Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study.

ABSTRACT:

Background and aims

In real-world, wild-type transthyretin cardiomyopathy is increasingly diagnosed in patients ≥ 80 years old (octogenarians), although being underrepresented in randomized clinical trials. Specific data on natural course and outcome under tafamidis treatment in octogenarians are therefore scarce. The impact of tafamidis treatment on mortality in real-world wild-type transthyretin cardiomyopathy octogenarians was studied.

Methods

An international, multicentre cohort study of 710 consecutive wild-type transthyretin cardiomyopathy patients with mean follow-up of 2.2 ± 1.8 years for all-cause mortality endpoint was performed.

Results

The cohort consisted of 58.5% (415/710) octogenarians (85 ± 4 years, 74.2% male). Before tafamidis availability, natural c

SUBMITTER: Debonnaire P 

PROVIDER: S-EPMC11905754 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature